Uutiset

Uutiset / Ajankohtaista

Linkkien avaamiseen ja lukemiseen tarvitset ilmaisen Acrobat Reader -ohjelman.

Otsikko Lataa koko teksti

29.6.2017

Servier  and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T

3.5..2017

Servier and miRagen extend collaboration for the research, developmant and commercialization of microRNA-targeting therapeutics

26.4.2017

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

25.4.2017

Servier and CTI BioPharma expand licence and collaboration agreemant to develop and commercialize Pixuvri

14.3.2017

Servier and Neurochlore join forces to treat autism in children

28.12.2017

OSE immunotherapeutics and Servier, partnership agreement to develop and commercialise OSE immunotherapeutics' Effi-7, an antagonist of the interleukin-7 receptor.

20.10.2016

New compound shows promise in treating multiple human cancers

23.6.2015

Ivabradiini (Procoralan) rajoitetusti erityiskorvattavaksi 1.7.2015 lähtien

16.6.2015

Taiho Pharmaceutical Co., Ltd. and Servier Enter into a Licence Agreement for Development and Commercialization of an oral Anticancer Drug in Europe

17.4.2015

FDA approves ivabradine for patients with chronic heart failure

12.11.2014

Intarcia and Servier sign ex-U.S. partnership for ITCA 650 in diabetes;Intarcia retains independence & full control in the U.S. & Japan

2.10.2014

Servier new reasearch partnership with the Walter and Eliza Hall Institute to target Achilles' heel of many cancers

26.9.2014

EMA Confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine)